20 names are moving together; 70% are participating in the current session.
Observed member paths adjusted against SPY. Shading marks the latest observation window.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorpor | Healthcare | -1.1% | 2/9 observed active sessions |
| IMCR | Immunocore Holdings plc | Healthcare | +1.6% | 3/9 observed active sessions |
| GMAB | Genmab A/S | Healthcare | -0.7% | Group member |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | +0.1% | Group member |
| INCY | Incyte Corporation | Healthcare | -2.2% | Group member |
| GILD | Gilead Sciences, Inc. | Healthcare | +1.2% | Group member |
| TBPH | Theravance Biopharma, Inc. | Healthcare | -0.2% | 3/9 observed active sessions |
| RDY | Dr. Reddy's Laboratories Ltd | Healthcare | -2.1% | Group member |
| ADMA | ADMA Biologics Inc | Healthcare | -1.3% | 1/9 observed active sessions |
| REGN | Regeneron Pharmaceuticals, Inc. | Healthcare | -0.2% | Group member |
| GSK | GSK plc | Healthcare | -0.9% | 1/9 observed active sessions |
| BMY | Bristol-Myers Squibb Company | Healthcare | +3.1% | Group member |
| BKD | Brookdale Senior Living Inc. | Healthcare | -0.0% | Group member |
| HALO | Halozyme Therapeutics, Inc. | Healthcare | -0.1% | 2/9 observed active sessions |
| NVS | Novartis AG | Healthcare | -0.4% | 3/9 observed active sessions |
| RPRX | Royalty Pharma plc | Healthcare | +0.1% | 2/9 observed active sessions |
| AMGN | Amgen Inc. | Healthcare | -0.8% | 1/9 observed active sessions |
| SUPN | Supernus Pharmaceuticals, Inc. | Healthcare | -2.2% | 4/9 observed active sessions |
| TARS | Tarsus Pharmaceuticals, Inc. | Healthcare | +2.1% | 6/9 observed active sessions |
| ABBV | AbbVie Inc. | Healthcare | +0.0% | Group member |
Cohort
20 namesParticipation
70% this sessionObserved history
10 daily buildsFiling coverage
16/20 membersdemand / volume
“Our operating results may fluctuate due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following: • the cost of manufacturing XDEMVY or our other product candidates, which may vary depending on the quantity of production and the terms of our agreements with manufacturers; • the level of demand for XDEMVY or our product candidates should they receive approval, which may vary significantly;”
TARS 10-K
demand / volume affecting revenue
“Increases in demand on any of AbbVie's suppliers could result in delays and disruptions in the manufacturing, distribution and sale of its products and/or product shortages, leading to lost revenue.”
ABBV 10-K
credit / rates affecting interest expense
“These increases were partially offset by $1.1 million of increased interest expense related to our 2024 Credit Facility.”
TARS 10-K
This identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
HALOsupplier · Not moving with the group now
Filing receipt · TEVA / HALO
“We have commercialized auto-injector products with Teva Pharmaceutical Industries, Ltd.”
HALO · supplier
HALOpartner · Moving with the group now · 115 min observed
Filing receipt · PFE / HALO
“13 Table of Contents Pfizer Collaboration In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide licens…”
HALO · partner
BMRNcustomer · Not moving with the group now
Filing receipt · SNY / BMRN
“Sanofi is our sole customer for ALDURAZYME and is responsible for distributing, marketing, and selling ALDURAZYME to third parties.”
BMRN · customer
AMGNsupplier · Moving with the group now · 115 min observed
Filing receipt · ONC / AMGN
“Purchase Commitments As of June 30, 2025, non-cancellable purchase commitments amounted to $130.1 million, of which $32.6 million related to minimum purchase requirement…”
AMGN · supplier
ABBVcustomer · Not moving with the group now
Filing receipt · RGNX / ABBV
“As of December 31, 2025 and 2024, the Company had recorded $ 10.9 million and $ 11.3 million, respectively, due from AbbVie for net reimbursement of costs incurred for a…”
ABBV · customer